New pill shows promise in early trial for Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase study tests a new daily pill, NDI-219216, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, side effects, and whether the drug can shrink tumors. About 134 participants will take the pill dail…
Phase: PHASE1, PHASE2 • Sponsor: Nimbus Wadjet, Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC